Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
What role will minimal residual disease testing play in multiple myeloma?
Progress in mantle cell lymphoma over the last 15 years
Developments in multiple myeloma - immunotherapy and personalized medicine
The role of allogeneic stem cell transplantation in CLL